264 related articles for article (PubMed ID: 34155798)
1. Non-alcoholic fatty liver disease in type 2 diabetes - A specific entity?
Schröder B; Kahl S; Roden M
Liver Int; 2021 Jun; 41 Suppl 1():105-111. PubMed ID: 34155798
[TBL] [Abstract][Full Text] [Related]
2. Role of Patatin-Like Phospholipase Domain-Containing 3 Gene for Hepatic Lipid Content and Insulin Resistance in Diabetes.
Zaharia OP; Strassburger K; Knebel B; Kupriyanova Y; Karusheva Y; Wolkersdorfer M; Bódis K; Markgraf DF; Burkart V; Hwang JH; Kotzka J; Al-Hasani H; Szendroedi J; Roden M;
Diabetes Care; 2020 Sep; 43(9):2161-2168. PubMed ID: 32910776
[TBL] [Abstract][Full Text] [Related]
3. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
4. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
5. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
Budd J; Cusi K
Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
[TBL] [Abstract][Full Text] [Related]
6. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
7. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review.
Zachou M; Flevari P; Nasiri-Ansari N; Varytimiadis C; Kalaitzakis E; Kassi E; Androutsakos T
Eur J Clin Pharmacol; 2024 Jan; 80(1):127-150. PubMed ID: 37938366
[TBL] [Abstract][Full Text] [Related]
8. A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?
Vincent RK; Williams DM; Evans M
Diabetes Obes Metab; 2020 Dec; 22(12):2227-2240. PubMed ID: 32945071
[TBL] [Abstract][Full Text] [Related]
9. Association of Genetic Non-alcoholic Fatty Liver Disease with Insulin Resistance-Are we Different?
Karoli R; Fatima J; Singh PS; Siddiqi Z; Varshney S; Beg MS; Khan MA
J Assoc Physicians India; 2019 Mar; 67(3):34-38. PubMed ID: 31304703
[TBL] [Abstract][Full Text] [Related]
10. The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment.
Cariou B
Diabetes Obes Metab; 2022 Feb; 24 Suppl 2():15-27. PubMed ID: 35014161
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial.
Della Pepa G; Russo M; Vitale M; Carli F; Vetrani C; Masulli M; Riccardi G; Vaccaro O; Gastaldelli A; Rivellese AA; Bozzetto L
Diabetes Res Clin Pract; 2021 Aug; 178():108984. PubMed ID: 34311022
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans.
Pafili K; Roden M
Mol Metab; 2021 Aug; 50():101122. PubMed ID: 33220492
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.
Yabiku K
Front Endocrinol (Lausanne); 2021; 12():768850. PubMed ID: 34950104
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic fatty liver disease: Evolving paradigms.
Lonardo A; Nascimbeni F; Maurantonio M; Marrazzo A; Rinaldi L; Adinolfi LE
World J Gastroenterol; 2017 Sep; 23(36):6571-6592. PubMed ID: 29085206
[TBL] [Abstract][Full Text] [Related]
15. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes.
Cusi K; Sanyal AJ; Zhang S; Hartman ML; Bue-Valleskey JM; Hoogwerf BJ; Haupt A
Diabetes Obes Metab; 2017 Nov; 19(11):1630-1634. PubMed ID: 28417532
[TBL] [Abstract][Full Text] [Related]
16. Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map.
Kumar J; Memon RS; Shahid I; Rizwan T; Zaman M; Menezes RG; Kumar S; Siddiqi TJ; Usman MS
Dig Liver Dis; 2021 Jan; 53(1):44-51. PubMed ID: 32912770
[TBL] [Abstract][Full Text] [Related]
17. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
Doumas M; Imprialos K; Stavropoulos K; Athyros VG
Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
[TBL] [Abstract][Full Text] [Related]
18. [Non-Alcoholic Fatty Liver Disease and Diabetes: the bad marriage].
Nascè A; Memaj P; Jornayvaz FR
Rev Med Suisse; 2023 May; 19(829):1090-1093. PubMed ID: 37260205
[TBL] [Abstract][Full Text] [Related]
19. The role of incretin hormones and glucagon in patients with liver disease.
Junker AE
Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
[TBL] [Abstract][Full Text] [Related]
20. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
